Format

Send to:

Choose Destination
See comment in PubMed Commons below
Br J Pharmacol. 2006 May;148(1):4-6.

Ranolazine and late cardiac sodium current--a therapeutic target for angina, arrhythmia and more?

Author information

  • 1Department of Medicine, Cardiovascular Medicine Section, University of Wisconsin, Madison, WI 53705, USA. jcm@medicine.wisc.edu

Abstract

Ranolazine is a new antianginal drug approved for clinical use in the United States in January 2006. A study published in this same issue of the British Journal of Pharmacology characterizes ranolazine block of late sodium current caused by the long QT syndrome 3 mutations. This commentary discusses the implications of that study and the background and implications for block of late cardiac sodium current in general.

PMID:
16520741
[PubMed - indexed for MEDLINE]
PMCID:
PMC1617040
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Blackwell Publishing Icon for PubMed Central
    Loading ...
    Write to the Help Desk